Industry Seeks Changes In FDA Drug/Diagnostic Co-Development Model
This article was originally published in The Gray Sheet
Executive Summary
FDA should employ more realistic timelines for drug/diagnostic co-development when it crafts draft guidance on the topic, stakeholders argue in written comments to the agency